FLSM
EOLS icon

Frazier Life Sciences Management’s Evolus EOLS Stock Holding History

Frazier Life Sciences Management’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Hold
2,630,665
– – 0.4% 35
2026
Q1 		$10.8M Hold
2,630,665
– – 0.28% 33
2025
Q4 		$17.5M Hold
2,630,665
– – 0.47% 32
2025
Q3 		$16.2M Buy
2,630,665
+195,115
+8% +$1.52M 0.48% 33
2025
Q2 		$22.4M Buy
+2,435,550
New +$24.9M 0.9% 24

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Frazier Life Sciences Management's EOLS Position: Q2 2026 in Review

Frazier Life Sciences Management held its Evolus (EOLS) position steady in Q2 2026 at 2,630,665 shares worth $18.3M. The position accounts for 0.4% of the portfolio, ranked #35.

Frazier Life Sciences Management first reported a position in EOLS in Q2 2025 and has held it in 5 quarters since. The position peaked at $22.4M in Q2 2025. 158 funds tracked by Wall St. Rank hold EOLS as of Q2 2026.

  • Frazier Life Sciences Management held 2,630,665 shares of Evolus worth $18.3M as of Q2 2026.
  • Frazier Life Sciences Management left its Evolus share count unchanged in Q2 2026.
  • Evolus made up 0.4% of Frazier Life Sciences Management's portfolio in Q2 2026, its #35 holding.
  • Frazier Life Sciences Management first reported a position in Evolus in Q2 2025 and has held it in 5 quarters since.
  • Frazier Life Sciences Management's Evolus position peaked at $22.4M in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Evolus as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.